Paula Maria Cevaal

Ms. Paula Maria Cevaal

Department of Microbiology and Immunology, The University of Melbourne, Melbourne, Victoria, Australia
+1
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 February 2021 in ACS Nano
Verified
Journal Article
Closed access
PCPaula Maria Cevaal
Paula Maria Cevaal
AAAbdalla Ali
Abdalla Ali
ECEwa Czuba-Wojnilowicz
Ewa Czuba-Wojnilowicz
JSJori Symons
Jori Symons
Sharon LewinSharon Lewin
Sharon Lewin
FCFrank Caruso
Frank Caruso

29 May 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
PCPaula Maria Cevaal
Paula Maria Cevaal
SKStanislav Kan
Stanislav Kan
BFBridget M. Fisher
Bridget M. Fisher
MMMichael A. Moso
Michael A. Moso
ATAbigail Tan
Abigail Tan
MRMichael Roche
Michael Roche
A major hurdle to curing HIV is the persistence of integrated proviruses in resting CD4+ T cells that remain in a transcriptionally silent, latent state. One strategy to eradicate latent HIV is to activate viral transcription, followed by elimination of infected cells through virus-mediated cytotoxicity or immune-mediated clearance. We hypothesised that mRNA-lipid nanoparticle (LNP) technology would provide an opportunity to deliver mRNA encoding proteins able to reverse HIV latency in resting CD4+ T cells. Here we develop an LNP formulation (LNP X) with unprecedented potency to deliver mRNA to hard-to-transfect resting CD4+ T cells in the absence of cellular toxicity or activation. Encapsulating an mRNA encoding the HIV Tat protein, an activator of HIV transcription, LNP X enhances HIV transcription in ex vivo CD4+ T cells from people living with HIV. LNP X further enables the delivery of clustered regularly interspaced short palindromic repeats (CRISPR) activation machinery to modulate both viral and host gene transcription. These findings offer potential for the development of a range of nucleic acid-based T cell therapeutics.

3 March 2021 in ACS Applied Bio Materials
Verified
Journal Article
Closed access
SRShwathy Ramesan
Shwathy Ramesan
ARAmgad Rezk
Amgad Rezk
PCPaula Maria Cevaal
Paula Maria Cevaal
CCChristina Cortez-Jugo
Christina Cortez-Jugo
JSJori Symons
Jori Symons
Leslie YeoLeslie Yeo
Leslie Yeo

1 July 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
PCPaula Maria Cevaal
Paula Maria Cevaal
AAAbdalla Ali
Abdalla Ali
MDMarcel Doerflinger
Marcel Doerflinger
CCChristina Cortez-Jugo
Christina Cortez-Jugo
ATAbigail Tan
Abigail Tan
Sharon LewinSharon Lewin
Sharon Lewin
T cells are critically important to many diseases but are traditionally difficult to transfect. We hypothesise that the delivery of therapeutic cargo to T cells can be improved by targeting nanoparticles to surface receptors that undergo rapid receptor-mediated endocytosis. Using an internalisation assay that labelled intracellular and surface proteins with different fluorophores, we find that CD2 and CD7 exhibit significantly higher internalisation than other T cell receptors, such as CD3 or CD4. Targeting CD2 and CD7 improves nanoparticle internalisation by non-stimulated, primary CD4 + T cells and enhances the specificity of association to CD4 + T cells. Similarly, functionalising mRNA-lipid nanoparticles with antibodies targeting CD2 or CD7 enhances mRNA delivery to CD4 + T cells in vitro. Importantly, targeting CD2 or CD7 enables efficient lipid nanoparticle-mediated delivery of mRNA to T cells in blood and lymphoid tissue in vivo, demonstrating that targeting T cell receptor endocytosis can enhance nanoparticle-mediated drug delivery to T cells.

21 May 2022 in Viruses
Verified
Journal Article
Open access
PDF file
KTKiho Tanaka
Kiho Tanaka
PCPaula Maria Cevaal
Paula Maria Cevaal
RPRachel Pascoe
Rachel Pascoe
Three early-career female virologists sat down with a distinguished Nobel laureate to discuss two pandemics, 39 years apart